Building a Unified, Client-Focused, Early Stage CRO Through Strategic Expansion and Service Development Powers 448% Revenue Growth from Fiscal Year 2021 to Fiscal Year 2024 WEST LAFAYETTE, Ind., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 182 nd on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech... Read More

WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on... Read More

Preliminary Expected Fourth Quarter 2025 Revenue of $137.5 to $138.5 Million Preliminary Expected Full Year 2025 Revenue of $512.5 to $513.5 Million Updated Time of Company Presentation at Jefferies Global Healthcare Conference WEST LAFAYETTE, Ind., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical... Read More

WEST LAFAYETTE, Ind., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will... Read More

WEST LAFAYETTE, Ind., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will... Read More

In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the revolving credit facility has been corrected. The corrected release follows: – Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4:30 pm ET WEST... Read More

Third quarter fiscal 2025 revenue up 23.5% to $130.7 million Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and... Read More

WEST LAFAYETTE, Ind., July 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 third quarter ended June 30, 2025, on Wednesday, August 6,... Read More

WEST LAFAYETTE, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer will present at the upcoming Jefferies Global Healthcare... Read More

Second quarter fiscal 2025 revenue increased 4.4% to $124.3 million Year-to-date fiscal 2025 revenue declined 4.1% to $244.2 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models... Read More

WEST LAFAYETTE, Ind., April 23, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 second quarter ended March 31, 2025, on Wednesday, May 7,... Read More

Sea's pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug (IND)-enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) Pre-clinical development work by Inotiv, Inc. to support Sea... Read More

Enhanced liquidity by $27.5 million through the issuance of 6.9 million common shares First quarter fiscal 2025 revenue declined 11.5% to $119.9 million Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services... Read More

WEST LAFAYETTE, Ind., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 first quarter ended December 31, 2024, on Wednesday,... Read More

WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced... Read More

WEST LAFAYETTE, Ind., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised approximately $24.0 million in net proceeds from its underwritten public offering of 6,000,000 common shares at... Read More

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the pricing of its underwritten public offering of 6,000,000 common shares at a price to the public of $4.25 per share. In... Read More

WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The... Read More

Enhanced liquidity through issuance of Second Lien Notes Obtained amendment to credit agreement and extended note payable Fourth quarter fiscal 2024 revenue down 7.3% to $130.4 million Full year fiscal 2024 revenue down 14.3% to $490.7 million Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization... Read More

WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 138 on the Deloitte Technology Fast 500 ™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America. Over the last five years Inotiv grew 847%. Inotiv’s president and chief executive officer, Robert Leasure, Jr., credits the company’s growth trajectory... Read More

WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 fourth quarter and full year ended September 30, 2024, on... Read More

WEST LAFAYETTE, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, will present at the upcoming Jefferies London Global... Read More

WEST LAFAYETTE, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, has amended certain terms of its Credit Agreement. In addition, Inotiv has closed the sale of $22.6 million aggregate principal amount... Read More

WEST LAFAYETTE, Ind., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., Inotiv’s President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the 8 th... Read More

Third quarter fiscal 2024 revenue down 32.8% to $105.8 million Year-to-date fiscal 2024 revenue down 16.5% to $360.3 million Conclusion of certain government investigations Site optimization projects complete Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and... Read More

WEST LAFAYETTE, Ind., July 25, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, on Thursday, August 8,... Read More

WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provided the following business updates: Hillcrest, U.K. expansion project completed Extension of the maturity date of the $3.7... Read More

WEST LAFAYETTE, Ind., June 03, 2024 (GLOBE NEWSWIRE) -- Inotiv Inc. – Inotiv Inc. (“Inotiv” or the “Company”) (Nasdaq: NOTV), a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models, today announced that it reached an agreement with the U.S. Department of Justice (“DOJ”) to resolve a previously-announced criminal investigation into... Read More

WEST LAFAYETTE, Ind., May 23, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in the... Read More

Second quarter fiscal 2024 revenue down 21.5% to $119.0 million Year-to-date fiscal 2024 revenue down 7.2% to $254.5 million Agreement in principle reached with the U.S. Department of Justice on related matter Site optimization projects near completion Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., May 15, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research... Read More

WEST LAFAYETTE, Ind., May 14, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Wednesday, May 15,... Read More

WEST LAFAYETTE, Ind., May 09, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the release of the Company’s financial results for the three and six months ended March 31, 2024 and the conference call to... Read More

WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Friday, May 10,... Read More

First quarter fiscal 2024 revenue up 10.3% to $135.5 million First quarter fiscal 2024 DSA revenue up 8.8% to $44.7 million and RMS revenue up 11.1% to $90.8 million Shift to a renewed focus on sales and marketing as near-term infrastructure projects near completion Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading... Read More

WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 first quarter ended December 31, 2023, on Wednesday,... Read More

Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing expected to drive continued growth of fiscal 2024 DSA revenues Anticipate achieving the balance of expected expense reductions in fiscal 2024 Conference call begins today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 11, 2023 (GLOBE... Read More

WEST LAFAYETTE, Ind., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will be partnering with Vanguard Supply Chain Solutions LLC, the Company’s current provider of transportation... Read More

WEST LAFAYETTE, Ind., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 fourth quarter and full year ended September... Read More

WEST LAFAYETTE, Ind., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today provides business updates related to Inotiv’s operations and an update regarding its participation in upcoming investor conferences. Robert Leasure, Jr.,... Read More

WEST LAFAYETTE, Ind., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 127 on the Deloitte Technology Fast 500 ™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29 th year. Inotiv grew 1156% during this period. Inotiv’s president and chief executive officer, Robert Leasure, Jr., credits a purpose-driven,... Read More

WEST LAFAYETTE, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming... Read More

WEST LAFAYETTE, Ind., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization, today announced the appointment of Terry Coelho to its Board of Directors. Ms. Coelho is replacing Richard A. Johnson PhD, who is leaving the Board as part of the Board’s succession planning. Ms. Coelho was also appointed to serve as a member of the Compensation Committee and the Audit Committee, and... Read More

WEST LAFAYETTE, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced the completion of the sale of its businesses in Israel. The sale complements Inotiv’s site optimization... Read More

WEST LAFAYETTE, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer,... Read More

WEST LAFAYETTE, Ind., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q3 FY 2023”) and nine months (“YTD FY 2023”) ended June 30, 2023.... Read More

WEST LAFAYETTE, Ind., July 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, on... Read More

WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer,... Read More

WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today its participation in the following investor conferences: Benchmark Healthcare House Call Conference... Read More

WEST LAFAYETTE, Ind., May 11, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q2 FY 2023”) and six months (“YTD FY 2023”) ended March 31, 2023.... Read More

WEST LAFAYETTE, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, and research models and related products and services, announced today the expansion of the Company’s safety pharmacology offering with the validation and verification of a cardiopulmonary telemetry study model in... Read More

WEST LAFAYETTE, Ind., April 26, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 second quarter ended March 31, 2023, on... Read More

Inotiv offers fit-for-purpose drug testing approaches and quality-by-design methodologies to facilitate sample analysis accuracy, boosting clients' success rates. SAN ANTONIO , April 11, 2023 /CNW/ -- Recently, Frost & Sullivan assessed the bio-analytical testing services industry and, based on its findings, recognized Inotiv , Inc. (Nasdaq: NOTV) with the 2022 North American Customer Value Leadership Award. Inotiv addresses... Read More

WEST LAFAYETTE, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q1 FY 2023”) ended December 31, 2022. Financial Highlights Q1 FY... Read More

WEST LAFAYETTE, Ind., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022 on... Read More

WEST LAFAYETTE, Ind., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, announced today that it has earned the 2023 Top Workplaces USA award, issued by Energage , a purpose-driven organization... Read More

WEST LAFAYETTE, Ind., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that David Landman has been designated by Jermyn Street Associates LLC as its Shareholder Representative on... Read More

WEST LAFAYETTE, Ind., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months (“Q4 FY 2022”) and twelve months (“FY 2022”) ended September 30,... Read More

WEST LAFAYETTE, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 fourth quarter and full... Read More